Kremers Urban Pharmaceuticals Inc (CENT)

Currency in BDT
10.50
-0.20(-1.87%)
Delayed Data·

CENT Financial Summary

Key Ratios

P/E Ratio-30.97
Price/Book1.33
Debt / Equity31.78%
Return on Equity-4.82%
Dividend Yield0.00%
EBITDA-13.66M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
30/06
2016
30/06
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
* In Millions of BDT (except for per share items)

Earnings

Latest Release
Dec 24, 2024
EPS / Forecast
-- / --
Revenue / Forecast
8.48M / --
EPS Revisions
Last 90 days

FAQ

What were Kremers Urban Pharmaceuticals's earnings for the latest quarter?

The Kremers Urban Pharmaceuticals EPS (TTM) is -0.30. Kremers Urban Pharmaceuticals reported sales of 8.48, net income of -0.45, and EPS of 0.00 for the latest quarter.

What was Kremers Urban Pharmaceuticals's net income for the latest quarter?

Kremers Urban Pharmaceuticals's net income for the latest quarter was -0.45.

How did Kremers Urban Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from -72.94 in the previous quarter to 8.48 in the latest quarter, and net income moved from -4.94 to -0.45 compared to the previous quarter.

What is Kremers Urban Pharmaceuticals's net profit margin on a TTM basis?

Kremers Urban Pharmaceuticals's trailing twelve months (TTM) net profit margin is -143.31%.

How does Kremers Urban Pharmaceuticals's debt to equity ratio compare to industry standards?

Kremers Urban Pharmaceuticals's total debt-to-equity ratio is 31.78%.

What is Kremers Urban Pharmaceuticals's return on investment on a TTM basis?

Kremers Urban Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is -4.82%.

Did Kremers Urban Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Kremers Urban Pharmaceuticals's net change in cash was -0.51 million.

What were Kremers Urban Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Kremers Urban Pharmaceuticals reported total assets of 1,438.28 million and total liabilities of 332.70 million.

How has Kremers Urban Pharmaceuticals's total revenue grown this year?

Kremers Urban Pharmaceuticals's total revenue was -72.94 in the previous quarter and 8.48 in the latest quarter.

What is Kremers Urban Pharmaceuticals's gross margin on a TTM basis?

Kremers Urban Pharmaceuticals's trailing twelve months (TTM) gross margin is -305.44%.

What was Kremers Urban Pharmaceuticals's revenue per share for the latest quarter?

Kremers Urban Pharmaceuticals's revenue per share for the latest quarter was 132.75.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.